NCT07645924: A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- State
- Under way
- Phase
- Phase 3
- People
- 1,800 planned
- Started
- 1 Jul 2026
- Primary completion
- Feb 2027
- Arms
- Elismetrep 10 mg, Elismetrep 20 mg
- Results
- None posted
- 12 Jun 2026: Trial registered
- 1 Jul 2026: Trial started